Image courtesy of Hempel Family Assay Depot is pleased to announce the Rare Disease Science Challenge: Be HEARD (Helping Empower and Accelerate Research…

The Make Your Mark competition, part of Assay’s Depot’s Open Science Challenge series, is now officially live in San Diego, New York, and…

For decades the model for how a clinical diagnostic assay (otherwise known as a clinical diagnostic, or a diagnostic test) was developed remained…

Yesterday we published in Scientific American’s blog[1] – a call to action about the Assay Depot sponsored Rare Disease Science Challenge. If you…

Assay Depot is proud to announce that our own Kevin Lustig is one of the recipients of the 2012 PharmaVOICE 100 award, which…

Today, we look at our second winner of the Bay Area Open Science Challenge and his work. Derek Jacoby is studying gout treatment…

A couple of months ago, Assay Depot and BioCurious wrapped up it’s first Open Science Challenge. We had some great proposals submitted, but ultimately,…

Animal testing is critical to advancing science and learning more about disease, but what animals are effective? It’s safe to say that mice,…

The 2011-2012 school year is over, so we decided the next infographic should take a look at how the sciences are faring at…

We’ve looked at what happens to a drug when a patent expires, but what happens to the patent owner? As patents have expired and many blockbuster drugs become generic, pharmaceutical companies have looked to new drugs and innovations to replace the lost income. Getting a drug through regulatory hurdles, such as clinical trials and safety testing, is difficult and millions of dollars can be lost from an unexpected failure. As many patents have expired and only a few drugs have replaced them in the past decade, pharmaceutical companies have looked to mergers and acquisitions for new products and drugs in an effort to buy innovation.